Tech giant Apple (AAPL) unveiled the highly-anticipated iPhone Air at its annual product launch event in Cupertino, California on Tuesday.
The company described the new phone as “impossibly thin” at 5.6 millimetres thick but also “more durable than any previous model” with a grade 5 titanium frame.
Read more: Stocks rise as Trump asks EU to levy 100% tariffs on China and India
Apple also launched the iPhone 17 and iPhone 17 Pro and Pro Max, featuring improvements including upgraded cameras and batteries and better overall durability.
In addition, the company unveiled its latest Apple Watch lineup, which also promise improved durability among other features. Apple also debuted the Airpods Pro 3, offering improved audio and built-in heart rate tracking.
Despite the raft of product announcements, shares in Apple were little changed in pre-market trading on Wednesday.
Shares in Oracle soared 30% in pre-market trading on Wednesday, after the software company offered a bullish revenue outlook.
In first quarter results, released on Tuesday, Oracle CEO Safra Catz said: “We expect Oracle Cloud Infrastructure revenue to grow 77% to $18bn (£13.3bn) this fiscal year — and then increase to $32bn, $73bn, $114bn, and $144bn over the subsequent four years.”
The jump in shares came despite Oracle's first quarter earnings coming in below Wall Street expectations. The company reported revenue of $14.9bn, just shy of the $15bn expected by analysts polled by Bloomberg. The software giant's adjusted earnings per share of $1.47 also came in below the projected $1.48.
Read more: Oil prices rise on Middle East tensions and Trump’s tariff push
At the same time, Catz said that Oracle had signed four multi-billion-dollar contracts with three different customers in the first quarter.
“It was an astonishing quarter—and demand for Oracle Cloud Infrastructure continues to build,” she said. “Over the next few months, we expect to sign-up several additional multi-billion-dollar customers and RPO [recovery point objective] is likely to exceed half-a-trillion dollars.”
Ozempic-maker Novo Nordisk (NOVO-B.CO) announced on Wednesday that it planned to cut 9,000 jobs globally, as part of efforts to “streamline operations”.
The Danish pharmaceuticals company said around 5,000 of the job losses would be in Denmark and expected the overall cuts to deliver annualised savings of 8 billion Danish krone (£926m) by the end of 2026.
However, Novo Nordisk said one-off restructuring costs of 8 billion Danish krone would lead to an updated full-year 2025 operating profit growth outlook of 4% to 10%, compared to a previous range of 10% to 16%.